taflinlar
Roche submits melanoma drug to FDA
December 15, 2014Sales and Marketing Cobimeinib, FDA, Roche, Zelboraf, mekinist, melanoma, taflinlar, vemurafenib
Roche has submitted its melanoma drug cobimeinib for review with the FDA as it confirms the results of its Phase …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
